Rosiglitazone evaluated for cardiovascular outcomes and regulation of

Abstract:

Rosiglitazone is an insulin sensitiser used for the treatment of type 2 diabetes. After reports of serious adverse events associated with rosiglitazone, concerns were raised about increased frequency of myocardial infarction and cardiovascular death in patients treated with rosiglitazone. The RECORD study was a multicentre, open-label trial including 4447 patients with type 2 diabetes mellitus who were randomly assigned to either rosiglitazone or control group. The primary endpoint was cardiovascular hospitalization or cardiovascular death. Addition of rosiglitazone to the existing treatment did not increase the risk of cardiovascular morbidity or mortality in study participants, but it was associated with an increased risk of heart failure and bone fractures, particularly in female patients. As patients with diabetes mellitus already have an increased risk of cardiovascular morbidity and mortality, addition of rosiglitazone to the existing treatment of patients with type 2 diabetes mellitus and cardiovascular complications requires increased caution. Properly selected patients may achieve satisfactory glycaemic control with rosiglitazone. 

Key words:
diabetes mellitus, type 2; mortality, cardiovascular diseases; myocardial infarction; rosiglitazone